Hempshire Group Past Earnings Performance
Past criteria checks 0/6
Hempshire Group's earnings have been declining at an average annual rate of -284.3%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 52% per year.
Key information
-284.3%
Earnings growth rate
-87.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -52.0% |
| Return on equity | -341.4% |
| Net Margin | -4,683.0% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Hempshire Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -7 | 2 | 0 |
| 30 Jun 22 | 0 | -6 | 2 | 0 |
| 31 Mar 22 | 0 | -3 | 2 | 0 |
| 31 Dec 21 | 0 | -2 | 2 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
Quality Earnings: HMPS.F is currently unprofitable.
Growing Profit Margin: HMPS.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if HMPS.F's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare HMPS.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HMPS.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: HMPS.F has a negative Return on Equity (-341.45%), as it is currently unprofitable.